AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI9929 After Single Administration in Healthy Male Japanese Subjects
- First Posted Date
- 2013-07-31
- Last Posted Date
- 2014-02-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 64
- Registration Number
- NCT01913028
- Locations
- 🇯🇵
Research Site, Fukuoka-shi, Japan
🇯🇵Kyushu Clinical Pharmacology Research Clinic, Medical Co. LTA, Fukuoka, Hakata, Japan
Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2013-07-25
- Last Posted Date
- 2016-03-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 933
- Registration Number
- NCT01908140
- Locations
- 🇬🇧
Almirall Investigational Site, Sidcup, United Kingdom
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder
Phase 2
Completed
- Conditions
- Tourette Syndrome
- Interventions
- Drug: AZD5213 and placebo
- First Posted Date
- 2013-07-22
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 29
- Registration Number
- NCT01904773
- Locations
- 🇺🇸
Research Site, Salt Lake City, Utah, United States
To Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of Olaparib, and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation to Patients With Advanced Solid Tumours
Phase 1
Completed
- Conditions
- Solid Tumours
- Interventions
- First Posted Date
- 2013-07-16
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 85
- Registration Number
- NCT01900028
- Locations
- 🇩🇰
Research site, Herlev, Denmark
🇬🇧Research Site, Sutton, United Kingdom
Dyslipidemia Management in Chinese Post Stroke Patients
Completed
- Conditions
- Brain Ischemia,Stoke
- First Posted Date
- 2013-07-12
- Last Posted Date
- 2015-07-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5000
- Registration Number
- NCT01897883
- Locations
- 🇨🇳
Research Site, Shanghai, China
Comparison of Two Formulations of AZD5363 and the Effect of Food on Pharmacokinetic Exposure, Safety and Tolerability
Phase 1
Completed
- Conditions
- Advanced Solid Malignancy,Safety and Tolerability,Pharmacokinetics, Pharmacodynamics,Tumour Response,
- Interventions
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2016-05-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 33
- Registration Number
- NCT01895946
- Locations
- 🇬🇧
Research Site, Surrey, United Kingdom
Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment
- First Posted Date
- 2013-07-10
- Last Posted Date
- 2019-09-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 31
- Registration Number
- NCT01894243
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or Impaired Kidney Function
- First Posted Date
- 2013-07-10
- Last Posted Date
- 2016-10-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 56
- Registration Number
- NCT01894256
- Locations
- 🇬🇧
Research Site, Surrey, United Kingdom
Distribution of Neutrophils in Bronchial Mucosal Tissue in Asthma Patients Before and After 4 Weeks Treatment With AZD 5069
- First Posted Date
- 2013-07-01
- Last Posted Date
- 2016-02-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 13
- Registration Number
- NCT01890148
- Locations
- 🇩🇪
Research Site, Grosshansdorf, Germany
Risk of Uncomplicated Peptic Ulcer in the General Population
Completed
- Conditions
- Peptic Ulcer [Iowa Type (107680.0010)]
- Interventions
- Drug: Risk of symptomatic peptic ulcer
- First Posted Date
- 2013-06-28
- Last Posted Date
- 2014-07-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4000
- Registration Number
- NCT01888588
- Locations
- 🇪🇸
Research Site, Madrid, Spain